ArticleFood science & nutrition2025
Shikonin Ameliorates Alcohol-Associated Liver Disease by Reducing Oxidative Stress, Apoptosis, and Inflammation.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Shikonin-Loaded Nanoparticles Ameliorate DEHP-Exacerbated Psoriasis Skin Injury via Targeted Inhibition of the p38 MAPK Signaling Pathway.International journal of molecular sciences · 2026Article
- Ultra-Micro Powder From Edible Plants (Food science & nutrition · 2026Article
- Alkannin Protects Against UVB-Induced Skin Photoaging by Targeting Keap1 to Activate the Nrf2/HO-1 Pathway.Molecules (Basel, Switzerland) · 2026Article
- Shikonin Ameliorates Alcohol-Associated Liver Disease by Reducing Oxidative Stress, Apoptosis, and Inflammation.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol-associated liver disease (ALD) represents a major global health concern due to its significant contribution to morbidity and mortality. The development of ALD is largely driven by oxidative stress, inflammation, and apoptosis. Shikonin (SKN) is a natural extract possessing both antioxidant and anti-inflammatory properties. This study investigated the protective effects of SKN against ALD in an in vivo rat model of ALD induced by daily gavage with 52% alcohol for 6 weeks. Following this, SKN was administered, and its antioxidant, anti-inflammatory, and anti-apoptotic properties were examined. Results demonstrated that SKN treatment inhibited the alcohol-induced increase of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total cholesterol (TC), triglycerides (TG), lipopolysaccharide (LPS), reactive oxygen species (ROS), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) in serum and liver tissue, while enhancing the anti-inflammatory factor IL-10. Moreover, SKN mitigated alcohol-induced histological changes in liver tissues. In addition, the administration of SKN led to the restoration of hepatic superoxide dismutase (SOD) levels while reducing malondialdehyde (MDA) levels. Western blot revealed that SKN notably decreased Keap1 expression and elevated the expression of Nrf2 and HO-1 proteins, thereby enhancing the antioxidant capacity. In addition, SKN mitigated inflammation by inhibiting the TLR4/MyD88/NF-κB pathway. Furthermore, SKN administration inhibited the expression of Bax and Caspase3, while upregulating the anti-apoptotic protein Bcl-2, thereby reducing hepatocyte injury through the inhibition of apoptosis. Overall, these results indicated that SKN could ameliorate ALD by mitigating oxidative stress, apoptosis, and inflammation, positioning it as a promising natural extract for preventing and treating ALD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.